U

UTHR

United Therapeutics Corp.

294.28

19.58+7.13%
After Hours: 294.00  -0.28  -0.10%19:26 08/01 EDT
1D
5D
Daily
Weekly
Monthly
Quarterly
Yearly
OPEN/PREV CLOSE284.65/274.70
TODAY RANGE283.01-296.60
VOL2.43M
MARKET CAP13.31B
52 WEEK RANGE266.98-417.82
AVG VOL (3M)576.95K
% TURNOVER5.37%
TURNOVER--
P/E (TTM)11.48
% RANGE4.95%
EPS(TTM)25.64
P/E(FORWARD)11.08
P/B1.855
BVPS158.65
DIVIDEND--
P/S4.585
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP13.07B
SHARES OUTSTANDING45.23M
NEXT EARNINGS10/28-11/03
FREE FLOAT44.43M
LOT SIZE1
EX-DATE09/23/2009
Same Industry
Name/Symbol
Change%
Price

M

McKesson

MCK

+0.76%
698.80

B

Biogen Inc

BIIB

+3.09%
131.95

A

Amgen Inc

AMGN

+0.60%
296.88

S

Shire

SHPG

--
179.20

B

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%
0.0301

L

Lilly Eli & Co

LLY

+3.01%
762.33

C

Celgene

CELG

--
108.24

T

Therapeuticsmd Inc

TXMD

-0.89%
1.11

J

Johnson & Johnson

JNJ

+1.57%
167.33

A

Abbvie Inc

ABBV

+3.28%
195.22

Z

Zoetis Inc

ZTS

+1.09%
147.38

G

Gilead Sciences Inc

GILD

+0.79%
113.18

N

Novo-Nordisk A/S

NVO

+2.38%
48.19

B

Bristol-Myers Squibb Co

BMY

+2.12%
44.23

A

Alexion Pharms

ALXN

+1.70%
182.50

P

Pfizer

PFE

+0.86%
23.49

S

Sanofi FR

SNY

+2.43%
46.75

S

Sanofi FR

GCVRZ

0.00%
0.8711

N

Novartis

NVS

+1.37%
115.30

D

Dr Reddys Labs

RDY

-1.97%
13.94
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.